The potential of targeting Ras proteins in lung cancer

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 4, 2015, Pages 451-454

  McCormick, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenocarcinoma; drug discovery; Ras; targeting proteins

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; GUANOSINE TRIPHOSPHATE; NANOPARTICLE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

CELL MEMBRANE; CODON; CRYSTAL STRUCTURE; GENE MUTATION; HUMAN; IMMUNE SYSTEM; LUNG ADENOCARCINOMA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PALMITOYLATION; PROTEIN PROCESSING; REVIEW; RNA INTERFERENCE; ADENOCARCINOMA; DRUG DESIGN; GENETICS; LUNG NEOPLASMS; MUTATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; LUNG NEOPLASMS; MUTATION; RAS PROTEINS; RNA INTERFERENCE;

EID: 84924915113     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.1000304     Document Type: Review

References (11)

1. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511(7511):543-50
2. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25(3):282-303
3. Stephen AG, Esposito D, Bagni RK, et al. Dragging ras back in the ring. Cancer Cell 2014;25(3):272-81
4. Young A, McCormick F. Oncogenic and wild-type ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 2013;3(1):112-23
5. Ostrem JM, Peters U, Sos ML, et al. K-ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2014;503(7477):548-51
6. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2014;150(6):1107-20
7. Zimmerman G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEδinteraction impairs oncogenic KRAS signaling. Nature 2013;497(7451):638-42
8. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;454(7291):1067-70
9. Yuan TL, Fellmann C, Lee CS, et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discovery 2014;4(10):1182-97
10. Xue W, Dahlman JE, Tammela T, et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 2014;111(34):E3553-61
11. Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Contr 2014;21(1):80-9